Document is current

Article History

Received: 3 July 2025

Accepted: 14 August 2025

First Online: 23 September 2025

Declarations

:

: Raphaele Seror declares consulting fees/honoraria from GlaxoSmithKline, Boehringer, Kiniska, Janssen, Astra ZENECA, alpha Sigma, Bristol Myers Squibb and Novartis; grant support: Roche and Novartis; and support for attending meetings from GlaxoSmithKline, Novartis, and Amgen. Jacques-Eric Gottenberg consulted for AbbVie, Bristol Myers Squibb, Galapagos, Gilead, Johnson & Johnson, Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. Federico Zazzetti, Andras Borsi, Wim Noel, Harman Dhatt, Angelina Villasis-Keever & Anna Sheahan are employees and shareholders of Johnson & Johnson Innovative Medicine and Johnson & Johnson Stockholder. Urbano Sbarigia was a Johnson & Johnson stockholder at the time of writing; employed by UCB after completion of the manuscript. Nicola Massey, Victoria Barton & Sarah Weatherby are employees of Adelphi Real World. Megan Hughes no longer works for Adelphi Real World, but did at the time of writing.

: Participants provided informed consent at the time of data collection using a checkbox. Physician and patient data were pseudo-anonymized, and a code was assigned when data were collected. Data were aggregated before being shared with the subscriber and/or for publication. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines [ ]. An exemption from ethical approval was obtained from Western International Review Board (protocol number AG8391). Each survey was performed in full accordance with the relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [ ], Health Information Technology for Economic and Clinical Health Act legislation [ ], and followed the principles of the Helsinki Declaration of 1964 and subsequent revisions.